Lupin Manufacturing Solutions (LMS) has announced a strategic alliance with PolyPeptide to bolster the global peptide supply chain. This collaboration seeks to improve supply chain resilience and boost readiness for the expanding peptides market. The alliance aims to support next-generation peptide therapeutics. It will expand sourcing options, integrate supply planning, and ensure superior service reliability. This partnership strengthens Lupin as a leading peptide CDMO supplier.
Strategic Alliance Overview
Lupin Manufacturing Solutions (LMS), a Lupin subsidiary, has entered a strategic alliance with PolyPeptide Group AG. The aim is to enhance the supply chain for peptide-based active pharmaceutical ingredients. This collaboration will improve operational efficiency and preparedness for the growing global peptide market.
Key Objectives of the Alliance
The alliance between Lupin and PolyPeptide will focus on several key areas:
- Expanding sourcing options for peptide APIs to meet global demand, especially for metabolic disease therapies.
- Integrating procurement and supply planning processes.
- Ensuring consistent quality and reliable service delivery.
Statements from Leadership
Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, stated that this alliance ensures access to specialized materials for large-scale commercial production, establishing secure and agile supply pathways.
Stéphane Varray, Chief Commercial Officer, PolyPeptide, highlighted that working with Lupin provides the necessary flexibility and supply chain depth to support growing customer demand and enable life-changing therapies.
Source: BSE
